BRPI0810192B8 - aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo. - Google Patents

aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo. Download PDF

Info

Publication number
BRPI0810192B8
BRPI0810192B8 BRPI0810192A BRPI0810192A BRPI0810192B8 BR PI0810192 B8 BRPI0810192 B8 BR PI0810192B8 BR PI0810192 A BRPI0810192 A BR PI0810192A BR PI0810192 A BRPI0810192 A BR PI0810192A BR PI0810192 B8 BRPI0810192 B8 BR PI0810192B8
Authority
BR
Brazil
Prior art keywords
same
methoxyimino
naphthyridine
diaza
spiro
Prior art date
Application number
BRPI0810192A
Other languages
English (en)
Inventor
Rack Choi Dong
Man Ryu Jei
Yang Jin
Kwang Ku Sae
Hwan Kim Seung
Hye Yoon Sue
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of BRPI0810192A2 publication Critical patent/BRPI0810192A2/pt
Publication of BRPI0810192B1 publication Critical patent/BRPI0810192B1/pt
Publication of BRPI0810192B8 publication Critical patent/BRPI0810192B8/pt
Publication of BRPI0810192C1 publication Critical patent/BRPI0810192C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

“aspartato do ácido 1-ciclopropil-6-fluoro- 7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-diidro- [1,8]naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo” são revelados sais de ácido aspártico do ácido 1- ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3,4]oct-6-il)-4-oxo-1,4- diidro-[1,8]naftiridina-3-carboxílico, métodos para sua preparação, e composições farmacêuticas antimicrobianas compreendendo o mesmo.
BRPI0810192A 2007-04-13 2008-04-14 aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo. BRPI0810192C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070036574 2007-04-13
PCT/KR2008/002106 WO2008127060A1 (en) 2007-04-13 2008-04-14 Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same

Publications (4)

Publication Number Publication Date
BRPI0810192A2 BRPI0810192A2 (pt) 2014-12-30
BRPI0810192B1 BRPI0810192B1 (pt) 2019-09-03
BRPI0810192B8 true BRPI0810192B8 (pt) 2019-09-10
BRPI0810192C1 BRPI0810192C1 (pt) 2021-05-25

Family

ID=39864109

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810192A BRPI0810192C1 (pt) 2007-04-13 2008-04-14 aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo.

Country Status (17)

Country Link
US (1) US8324238B2 (pt)
EP (1) EP2134712B1 (pt)
JP (1) JP5194105B2 (pt)
KR (1) KR100953271B1 (pt)
CN (1) CN101679416B (pt)
AU (1) AU2008239966C1 (pt)
BR (1) BRPI0810192C1 (pt)
CA (1) CA2683939C (pt)
CO (1) CO6251358A2 (pt)
DK (1) DK2134712T3 (pt)
EC (1) ECSP099736A (pt)
ES (1) ES2436140T3 (pt)
HK (1) HK1133881A1 (pt)
MX (1) MX2009011063A (pt)
PL (1) PL2134712T3 (pt)
PT (1) PT2134712E (pt)
WO (1) WO2008127060A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109108A (ko) 2007-06-12 2008-12-17 (주)엘티엠에이피 휴대단말기용 스텝 힌지
KR101468659B1 (ko) 2009-07-27 2014-12-05 주식회사 아리바이오 Ｒ-7-(3-아미노메틸-4-메톡시이미노-3-메틸-피롤리딘-1-일)-1-시클로프로필-6-플루오로-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 ｌ-아스파르트산염, 이의 제조방법 및 이를 포함하는 항균용 약학적 조성물
KR101646324B1 (ko) * 2014-03-04 2016-08-05 동화약품주식회사 1-시클로프로필-6-플루오로-7-(8-메톡시이미노-2,6-디아자-스피로[3,4]옥트-6-일)-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 디-아스파르트산염의 수화물 및 이를 포함하는 항균활성 조성물
CN103922987B (zh) * 2014-05-04 2016-09-28 苏州天马精细化学品股份有限公司 一种扎布沙星中间体及其合成方法
KR102213991B1 (ko) * 2014-05-20 2021-02-09 동화약품주식회사 개선된 자보플록사신의 제조방법
CN114894924A (zh) * 2022-04-21 2022-08-12 徐州医科大学 一种通过非衍生化gc-ms同时测定人血浆中4种抗癫痫药物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA824096B (en) * 1981-06-11 1983-04-27 Warner Lambert Co Salts of antimicrobial naphthyridine and quinoline compounds
HU188181B (en) 1981-06-11 1986-03-28 Warner-Lambert Co,Us Process for producing salts of naphtiridine and quinoline compounds of antimicrobial activity
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
KR960000223A (ko) * 1994-06-08 1996-01-25 김정순 신규한 피리돈 카르복실산 화합물을 함유한 수용액 및 이의 제조방법
CN1114607C (zh) * 1997-06-26 2003-07-16 同和药品工业株式会社 喹诺酮羧酸衍生物
DK1220678T3 (da) 1999-10-04 2007-07-09 John Carter Farmaceutiske præparater indeholdende kobber, salicylsyre og C-vitamin
RS51550B (en) * 2002-04-08 2011-06-30 Pfizer Inc. KAO DERIVATIVES KAO MODULATORS CCR5

Also Published As

Publication number Publication date
CN101679416A (zh) 2010-03-24
AU2008239966B2 (en) 2011-11-10
KR20080092893A (ko) 2008-10-16
CN101679416B (zh) 2012-06-27
KR100953271B1 (ko) 2010-04-16
BRPI0810192B1 (pt) 2019-09-03
JP5194105B2 (ja) 2013-05-08
CO6251358A2 (es) 2011-02-21
ES2436140T3 (es) 2013-12-27
AU2008239966A1 (en) 2008-10-23
WO2008127060A1 (en) 2008-10-23
CA2683939C (en) 2012-06-19
MX2009011063A (es) 2009-10-30
US8324238B2 (en) 2012-12-04
CA2683939A1 (en) 2008-10-23
BRPI0810192A2 (pt) 2014-12-30
PT2134712E (pt) 2013-11-26
EP2134712A4 (en) 2011-07-27
US20100184795A1 (en) 2010-07-22
JP2010523649A (ja) 2010-07-15
BRPI0810192C1 (pt) 2021-05-25
PL2134712T3 (pl) 2014-01-31
EP2134712B1 (en) 2013-08-21
HK1133881A1 (pt) 2010-04-09
AU2008239966C1 (en) 2012-03-29
DK2134712T3 (da) 2013-11-18
ECSP099736A (es) 2010-02-26
EP2134712A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
CY1119813T1 (el) Αλατα 2-φθορο-ν-μεθυλ-4-[7-(κινολιν-6-υλ-μεθυλ)-ιμιδαζο[1,2-β][1,2,4]τριαζιν-2-υλ]βενζαμιδιου και διαδικασιες που σχετιζονται με την παρασκευη αυτων
BRPI0810192B8 (pt) aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo.
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
TNSN07434A1 (en) Crystalline and other forms of 4-amino-5-fluoro-3- [6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
WO2010038081A3 (en) 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors
PT1928875E (pt) 2-amino-7,8-di-hidro-6h-pirido[4,3-d]pirimidin-5-onas
EP3626253A3 (en) Stable formulations of linaclotide
WO2007084221A9 (en) Methods and apparatus for identifying subject matter in view data
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
WO2007071965A3 (en) Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
AU2011307608A8 (en) Crystalline naloxol-PEG conjugate
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
SI1954251T1 (sl) Sestavek s počasnim sproščanjem, ki ima kot aktivno učinkovino Fe sol, postopek njegove priprave in uporabe
MX2009000768A (es) Lactamas macrociclicas.
TW200738723A (en) 1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof
WO2008009750A3 (en) Macrocyclic compounds useful as bace inhibitors
DK1976538T3 (da) Farmaceutisk formulering til behandling af slidgigt indeholdende clodronsyre og hyaluronsyre
MY140998A (en) New crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
EP2459550A4 (en) R-7- (3-aminomethyl-4-methoxyimino-3-METHYL-PYRROLIDIN-1-YL) -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro- [1,8] naphthyridine-3 CARBOXYLIC ACID AND L-ASPARINIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE FOR AN ANTIMICROBUM
DE60314920D1 (de) Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
IL210049A (en) Derivatives of h2 - pyrolo [4,3– c] quinoline, processes for their preparation, pharmacological uses thereof and pharmaceutical preparations containing them
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses
TN2010000363A1 (en) Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2539 DE 03/09/2019,QUANTO AO ITEM (43) DATA DA PUBLICACAO DO PEDIDO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2718 DE 07/02/2023 POR TER SIDO INDEVIDA.